Format

Send to

Choose Destination
See comment in PubMed Commons below
BMC Public Health. 2011 Oct 18;11:811. doi: 10.1186/1471-2458-11-811.

The case for conducting first-in-human (phase 0 and phase 1) clinical trials in low and middle income countries.

Author information

1
Department of Health Aging and Society, McMaster University, Hamilton, Ontario, L8S 4M4, Canada.

Abstract

BACKGROUND:

Despite the increase in the number of clinical trials in low and middle income countries (LMICs), there has been little serious discussion of whether First in Human (FIH; phase 0 and phase 1) clinical trials should be conducted in LMICs, and if so, under what conditions. Based on our own experience, studies and consultations, this paper aims to stimulate debate on our contention that for products meant primarily for conditions most prevalent in LMICs, FIH trials should preferably be done first in those countries.

DISCUSSION:

There are scientific and pragmatic arguments that support conducting FIH trials in LMIC. Furthermore, the changing product-development and regulatory landscape, and the likelihood of secondary benefits such as capacity building for innovation and for research ethics support our argument. These arguments take into account the critical importance of protecting human subjects of research while developing capacity to undertake FIH trials.

SUMMARY:

While FIH trials have historically not been conducted in LMICs, the situation in some of these countries has changed. Hence, we have argued that FIH should be conducted in LMICs for products meant primarily for conditions that are most prevalent in those contexts; provided the necessary protections for human subjects are sufficient.

PMID:
22008649
PMCID:
PMC3339411
DOI:
10.1186/1471-2458-11-811
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center